{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:27:58Z","timestamp":1781008078401,"version":"3.54.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed at negative regulatory components on T cells, such as cytotoxic T lymphocyte-associated antigen 4, programmed cell death-1 (PD-1), and its ligand, programmed cell death ligand-1. ICIs initate antitumor immunity; however, these agents are associated with immune-related adverse events (irAEs) that may affect a variety of organs. Renal irAEs most commonly present with asymptomatic acute kidney injury (AKI), which is often detected by routine laboratory testing. The severity of AKI associated with irAEs ranges from mild (grade 1\u20132) to severe (grade 3\u20134). It is often challenging to diagnose because this group of patients often have multiple reasons to have AKI (dehydration, sepsis, or nephrotoxic medication exposure). We present an illustrative case of a 60-year-old man with metastatic melanoma who presented with AKI during treatment with nivolumab and review the literature to address frequently asked questions concerning the diagnosis and management of renal irAEs in patients with advanced cancer. Importantly, most patients will recover completely, and some may tolerate a rechallenge of ICI therapy, with prompt and effective treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>Renal immune-related adverse events (irAEs) are less frequently reported than other irAEs; however, it is possible that available data underestimate their true incidence because of missed diagnoses and under-reporting. Although severe renal irAEs are more easily detected, smaller rises in creatinine may not be appreciated or may be attributed to other causes, because the differential diagnosis of acute kidney injury (AKI) in patients with cancer is broad. Baseline creatinine should be established prior to beginning immune checkpoint inhibitorss (ICIs), and it should be monitored with every cycle. If a patient develops AKI, the ICI should be held while the evaluation is pursued. A thorough workup of suspected renal irAEs must exclude other potential causes of AKI such as infection, dehydration, urinary tract obstruction, and nephrotoxin exposure. Acute kidney injury after ICI therapy does not appear to be more common in patients with baseline estimated glomerular filtration rate\u2009&amp;lt;60\u2009mL per min per 1.73\u2009m. One particular concern, however, is that those with baseline renal disease have less \u201crenal reserve,\u201d and repeated AKI events may push a patient closer to end-stage renal disease. Thus, clinicians must exert caution when rechallenging patients with pre-existing renal disease with ICI therapy in the event of a prior AKI from ICI-related allergic interstitial nephritis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0764","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T19:35:20Z","timestamp":1553283320000},"page":"735-742","source":"Crossref","is-referenced-by-count":51,"title":["Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review"],"prefix":"10.1093","volume":"24","author":[{"given":"Meghan E.","family":"Sise","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Seethapathy","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"key":"2021122507020443400_R1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122507020443400_R4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2021122507020443400_R8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122507020443400_R9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122507020443400_R10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2021122507020443400_R13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12882-018-0958-6","article-title":"Minimal change disease associated with anti-PD1 immunotherapy: A case report","volume":"19","author":"Gao","year":"2018","journal-title":"BMC Nephrol"},{"key":"2021122507020443400_R15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"Brom","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"2021122507020443400_R16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"2021122507020443400_R17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fonc.2017.00056","article-title":"Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers","volume":"7","author":"Maughan","year":"2017","journal-title":"Front Oncol"},{"key":"2021122507020443400_R18","first-page":"124","article-title":"Acute kidney injury is common in patients receiving checkpoint inhibitors [abstract]","volume":"29","author":"Seethapathy","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2021122507020443400_R19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2021122507020443400_R20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122507020443400_R21","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2215\/CJN.01330213","article-title":"Utility of urine eosinophils in the diagnosis of acute interstitial nephritis","volume":"8","author":"Muriithi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122507020443400_R22","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2215\/CJN.08620813","article-title":"Urinary eosinophils in AIN: Farewell to an old biomarker?","volume":"8","author":"Perazella","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122507020443400_R23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122507020443400_R24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122507020443400_R25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122507020443400_R26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ajkd.2012.05.002","article-title":"Urinary sediment findings in acute interstitial nephritis","volume":"60","author":"Fogazzi","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2021122507020443400_R27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5414\/CN108301","article-title":"Diagnosing drug-induced AIN in the hospitalized patient: A challenge for the clinician","volume":"81","author":"Perazella","year":"2014","journal-title":"Clin Nephrol"},{"key":"2021122507020443400_R28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122507020443400_R29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","article-title":"Cisplatin nephrotoxicity","volume":"23","author":"Arany","year":"2003","journal-title":"Semin Nephrol"},{"key":"2021122507020443400_R30","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122507020443400_R31","first-page":"191","article-title":"Clinical trials of cis-diamminedichloroplatinum (NSC-119875)","volume":"57","author":"Lippman","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"2021122507020443400_R32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1700980","article-title":"Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: Incidence and implications for hematologic recovery and clinical outcome","volume":"20","author":"Beyer","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2021122507020443400_R33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.ajkd.2012.02.330","article-title":"Bleeding complications of native kidney biopsy: A systematic review and meta-analysis","volume":"60","author":"Corapi","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2021122507020443400_R34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2215\/CJN.05750515","article-title":"The native kidney biopsy: Update and evidence for best practice","volume":"11","author":"Hogan","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 2","key":"2021122507020443400_R35","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"2021122507020443400_R36","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122507020443400_R37","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"2021122507020443400_R38","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2215\/CJN.01711105","article-title":"Mycophenolate mofetil for the treatment of interstitial nephritis","volume":"1","author":"Preddie","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122507020443400_R39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122507020443400_R40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J Transl Med"},{"key":"2021122507020443400_R41","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"2021122507020443400_R42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2021122507020443400_R43","first-page":"468","article-title":"Renal reserve in patients with solitary kidneys","volume":"15","author":"Rugiu","year":"1995","journal-title":"Semin Nephrol"},{"key":"2021122507020443400_R44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"2021122507020443400_R45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0764","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/735\/41917785\/oncolo_24_6_735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/735\/41917785\/oncolo_24_6_735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:02:31Z","timestamp":1640415751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/735\/6439418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,22]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0764","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2019,3,22]]}}}